+41 91 682 20 40
info@elixi-int.com
Reserved Area
Login
Register
Request Document
Send Document
Home
About Us
Services
Quality
News
Case Studies
Contact
Online Store
Let's talk
info@yourwebsite.com
+1 (555) 123-4567
Search
atypical hemolytic uremic syndrome to inhibit complement-mediated thrombotic microangiopathy
10 July 2019
FDA approves Soliris (eculizumab), first treatment for neuromyelitis optica spectrum disorder, a rare autoimmune disease of the central nervous system
by Elixi